Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-24T05:44:34.785Z Has data issue: false hasContentIssue false
  • English
  • Français

Corticolimbic changes in acetylcholine and cyclic guanosine monophosphate in the Flinders Sensitive Line rat: a genetic model of depression

Published online by Cambridge University Press:  24 June 2014

Linda Brand ,
Jurgens van Zyl ,
Estella L. Minnaar ,
Francois Viljoen ,
Jan L. du Preez ,
Gregers Wegener  and
Brian H. Harvey
Linda Brand*
Affiliation:
Division of Pharmacology, Unit for Drug Research and Development, School of Pharmacy, North-West University, Potchefstroom, South Africa
Jurgens van Zyl
Affiliation:
Division of Pharmacology, Unit for Drug Research and Development, School of Pharmacy, North-West University, Potchefstroom, South Africa
Estella L. Minnaar
Affiliation:
Division of Pharmacology, Unit for Drug Research and Development, School of Pharmacy, North-West University, Potchefstroom, South Africa
Francois Viljoen
Affiliation:
Division of Pharmacology, Unit for Drug Research and Development, School of Pharmacy, North-West University, Potchefstroom, South Africa
Jan L. du Preez
Affiliation:
Analytical Technology Laboratory, Unit for Drug Research and Development, School of Pharmacy, North-West University, Potchefstroom, South Africa
Gregers Wegener
Affiliation:
Centre for Psychiatric Research, University of Aarhus, Denmark
Brian H. Harvey
Affiliation:
Division of Pharmacology, Unit for Drug Research and Development, School of Pharmacy, North-West University, Potchefstroom, South Africa
*
Linda Brand, Division of Pharmacology, Unit for Drug Research and Development, School of Pharmacy, North-West University, 2520 Potchefstroom, South Africa. Tel: +27(18)2992233; Fax: +27(18)2992225; E-mail: linda.brand@nwu.ac.za
Get access Rights & Permissions [Opens in a new window]

Extract

Objective: Depression is suggested to involve disturbances in cholinergic as well as glutamatergic pathways, particularly the N-methyl-d-aspartate receptor-mediated release of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP). The aim of this study was to determine whether the Flinders Sensitive Line (FSL) rat, a genetic model of depression, presents with corticolimbic changes in basal acetylcholine (ACh) levels and NO/cGMP signalling.

Methods: Basal levels of nitrogen oxides (NOx) and both basal and l-arginine-stimulated nitric oxide synthase (NOS) formation of l-citrulline were analysed in hippocampus and frontal cortex in FSL and control Flinders resistant line (FRL) rats by fluorometric and electrochemical high-performance liquid chromatography, respectively. In addition, ACh and cGMP levels were analysed by liquid chromatography tandem mass spectrometry and radioimmunoassay, respectively.

Results: Significantly elevated frontal cortical but reduced hippocampal ACh levels were observed in FSL versus FRL rats. Basal cGMP levels were significantly reduced in the frontal cortex, but not hippocampus, of FSL rats without changes in NOx and l-citrulline, suggesting that the reduction of cGMP follows through an NOS-independent mechanism.

Conclusions: These data confirm a bidirectional change in ACh in the frontal cortex and hippocampus of the FSL rat, as well as provide evidence for a frontal cortical ACh-cGMP interaction in the depressive-like behaviour of the FSL rat.

Keywords

cGMPcholinergicFlinders Sensitive Line ratfrontal cortexhippocampusmajor depressionnitric oxide
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 24 , Issue 4 , August 2012 , pp. 215 - 225
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Millan, MJ.Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135–370.CrossRefGoogle ScholarPubMed
2.Fava, M, Kendler, KS.Major depressive disorder. Neuron 2000;283:35–341.Google Scholar
3.Sullivan, PF, Neale, MC, Kendler, KS.Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000;157:1552–1562.CrossRefGoogle ScholarPubMed
4.Anisman, H, Merali, Z, Stead, JDH.Experiential and genetic contributions to depressive- and anxiety-like disorders: clinical and experimental studies. Neurosci Biobehav Rev 2008;32:1185–1206.CrossRefGoogle ScholarPubMed
5.Mathé, AA, El Khoury, A, Gruber, SH.Gene-environment interaction in an animal model of depression. Eur Psychiatry 2008;23(Suppl. 2):S2.CrossRefGoogle Scholar
6.Thase, ME, Haight, BR, Richard, N et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005;66:974–981.CrossRefGoogle ScholarPubMed
7.Rosenzweig-Lipson, S, Beyer, CE, Hughes, ZA et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007;113:134–153.CrossRefGoogle ScholarPubMed
8.Krishnan, V, Nestler, EJ.The molecular neurobiology of depression. Nature 2008;455:894–902.CrossRefGoogle ScholarPubMed
9.Manji, HK, Quiroz, JA, Sporn, J et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003;53:707–742.CrossRefGoogle ScholarPubMed
10.Paul, IA, Skolnick, P.Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 2003;1003:250–272.CrossRefGoogle ScholarPubMed
11.Kleppisch, T, Feil, R.cGMP signalling in the mammalian brain: role in synaptic plasticity and behaviour. Handb Exp Pharmacol 2009;191:549–579.CrossRefGoogle Scholar
12.Feil, R, Kleppisch, T.NO/cGMP-dependent modulation of synaptic transmission. Handb Exp Pharmacol 2008;184:529–560.CrossRefGoogle Scholar
13.Prast, H, Philippu, A.Nitric oxide as modulator of neuronal function. Prog Neurobiol 2001;64:51–68.CrossRefGoogle ScholarPubMed
14.Harvey, BH.Affective disorders and nitric oxide: a role in pathways to relapse and refractoriness? Hum Psychopharmacol 1996;11:309–319.3.0.CO;2-B>CrossRefGoogle Scholar
15.Harvey, BH.Is major depressive disorder a metabolic encephalopathy? Hum Psychopharmacol 2008;23:371–384.CrossRefGoogle ScholarPubMed
16.Janowsky, DS, Davis, JM, El-Yousef, MK, Serkerke, HJ.A cholinergic adrenergic hypothesis of mania and depression. Lancet 1972;300:632–635.CrossRefGoogle Scholar
17.Overstreet, DH.Selective breeding for increased cholinergic function: development of a new animal model of depression. Biol Psychiatry 1986;21:49–58.CrossRefGoogle ScholarPubMed
18.Furey, ML, Drevets, WC.Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006;63:1121–1129.CrossRefGoogle ScholarPubMed
19.Brink, CB, Clapton, JD, Eagar, BE, Harvey, BH.Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J Neural Transm 2008;115:117–125.CrossRefGoogle ScholarPubMed
20.Liebenberg, N, Harvey, BH, Brand, L, Brink, CB.Antidepressant-like properties of phosphodiesterase 5 inhibitors and cholinergic dependency in a genetic rat model of depression. Behav Pharmacol 2010;21:540–547.CrossRefGoogle Scholar
21.De Vente, J.cGMP: a second messenger for acetylcholine in the brain? Neurochem Int 2004;45:799–812.CrossRefGoogle ScholarPubMed
22.De Vente, J, Van Ittersum, MM, Van Abeelen, J, Emson, PC, Axer, H, Steinbusch, HWM.NO-mediated cGMP synthesis in cholinergic neurons in the rat forebrain: effects of lesioning dopaminergic or serotonergic pathways on nNOS and cGMP synthesis. Eur J Neurosci 2000;12:507–519.CrossRefGoogle ScholarPubMed
23.Kraus, MM, Prast, H.The nitric oxide system modulates the in vivo release of acetylcholine in the nucleus accumbens induced by stimulation of the hippocampal fornix/ fimbria-projection. Eur J Neurosci 2001;14:1105–1112.CrossRefGoogle ScholarPubMed
24.Metherate, R, Ashe, JH.Synaptic interactions involving acetylcholine, glutamate, and GABA in rat auditory cortex. Exp Brain Res 1995;107:59–72.CrossRefGoogle ScholarPubMed
25.Sanacora, G, Gueorguieva, R, Epperson, CN et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004;61:705–713.CrossRefGoogle ScholarPubMed
26.Overstreet, DH.The Flinders sensitive line rat: a genetic animal model of depression. Neurosci Biobehav Rev 1993;17:51–68.CrossRefGoogle Scholar
27.Willner, P, Mitchell, PJ.The validity of animal models of predisposition to depression. Behav Pharmacol 2002;13:169–188.CrossRefGoogle ScholarPubMed
28.Neumann, ID, Wegener, G, Homberg, JR, Cohen, H, Slattery, DA, Zohar, J et al. Animal models of depression and anxiety: what do they tell us about human condition? Prog Neuropsychopharmacol Biol Psychiatry (in press ) , DOI:10.1016/j.pnpbp.2010.11.028.Google Scholar
29.Overstreet, DH, Friedman, E, Mather, AA, Yadid, G.The Flinders sensitive line rat: a selectively bred putative animal model of depression. Neurosci Biobehav Rev 2005;29:739–759.CrossRefGoogle Scholar
30.Wegener, G, Mathe, AA, Neumann, ID. Selectively bred rodents as models of depression and anxiety. In: Cryan, J, Reif, A, eds. Behavioral neurogenetics, (Current topics in behavioral neurosciences):Springer Verlag, 2011: 1866–3370.Google Scholar
31.Pucilowski, O, Overstreet, DH, Rezvani, AH, Janowsky, DS.Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression. Physiol Behav 1993;54:1215–1220.CrossRefGoogle Scholar
32.Wegener, G, Harvey, BH, Bonefeld, B et al. Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression. Int J Neuropsychopharmacol 2010;13:461–473.CrossRefGoogle Scholar
33.Daws, LC, Overstreet, DH.Ontogeny of muscarinic cholinergic supersensitivity in the Flinders sensitive line rat. Pharmacol Biochem Behav 1999;62:367–380.CrossRefGoogle ScholarPubMed
34.Overstreet, DH, Russell, RW, Crocker, AD, Schiller, GD.Selective breeding for differences in cholinergic funtion: pre- and postsynaptic mechanisms involved in sensitivity to the anticholinesterase, DFP. Brain Res 1984;294:327–332.CrossRefGoogle Scholar
35.Pepe, S, Overstreet, DH, Crocker, AD.Enhanced benzodiazepine responsiveness in rats with increased cholinergic function. Pharmacol Biochem Behav 1988;31:15–19.CrossRefGoogle ScholarPubMed
36.Zangen, A, Overstreet, DH, Yadid, G.Increased catecholamine levels in specific brain regions of a rat model of depression: normalization by chronic antidepressant treatment. Brain Res 1997;824:243–250.CrossRefGoogle Scholar
37.Nishi, K, Kanemaru, K, Diksic, M.A genetic rat model of depression, Flinders sensitive line, has a lower density of 5-HT1A receptors, but a higher density of 5-HT1B receptors, compared to control rats. Neurochem Int 2009;54:299–307.CrossRefGoogle Scholar
38.Elfving, B, Plougmann, PH, Müller, HK, Mathé, AA, Rosenberg, R, Wegener, G.Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int J Neuropsychopharmacol 2010;13:563–572.CrossRefGoogle Scholar
39.Elfving, B, Plougmann, PH, Wegener, G.Differential brain, but not serum VEGF levels in a genetic rat model of depression. Neurosci Lett 2010;19:474:13–16.CrossRefGoogle Scholar
40.Chen, F, Madsen, TM, Wegener, G, Nyengaard, JR.Imipramine treatment increases the number of hippocampal synapses and neurons in a genetic animal model of depression. Hippocampus 2010;20:1376–1384CrossRefGoogle Scholar
41.Schmidt, HHHW, Kelm, M. Determination of nitrite and nitrate by the Griess reaction. In: Feelisch, M, Stamler, JS, eds. Methods in nitric oxide research. Chichester, England: John Wiley and Sons, 1996:491–498.Google Scholar
42.Li, H, Meininger, CJ, Wu, G.Rapid determination of nitrite by reversed phase high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2000;746:199–207.CrossRefGoogle ScholarPubMed
43.Jobgen, WS, Jobgen, SC, Li, H, Meininger, CJ, Wu, G.Analysis of nitrite and nitrate in biological samples using high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007;851:71–82.CrossRefGoogle ScholarPubMed
44.Woitzik, J, Abromeit, N, Schaefer, F.Measurement of nitric oxide metabolites in brain microdialysates by a sensitive fluorometric high-performance liquid chromatography assay. Anal Biochem 2001;289:10–17.CrossRefGoogle ScholarPubMed
45.Bradford, MM.A rapid and sensitive method for the quantitation of microgramquantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.CrossRefGoogle Scholar
46.Pearce, WJ, Tone, B, Ashwal, S.Maturation alters cerebral NOS kinetics in the spontaneously hypertensive rat. Am J Physiol Regul Integr Comp Physiol 1997;273:R1367–R1373.CrossRefGoogle ScholarPubMed
47.Misko, TP, Schilling, RJ, Salvemini, D, Moore, WM, Currie, MG.A fluorometric assay for the measurement of nitrite in biological samples. Anal Biochem 1993;214:11–16.CrossRefGoogle ScholarPubMed
48.Dawson, TM, Snyder, SH.Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J Neurosci 1994;14:5147–5159.CrossRefGoogle ScholarPubMed
49.Fernandez-Cancio, MN, Fernandez-Vitos, EM, Centelles, JJ, Imperial, S.Sources of interference in the use of 2,3-diaminonaphthalene for the fluorimetric determination of nitric oxide synthase activity in biological samples. Clin Chim Acta 2001;312:205–212.CrossRefGoogle ScholarPubMed
50.Harvey, BH, Oosthuizen, F, Brand, L, Wegener, G, Stein, DJ.Stress restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus. Psychopharmacology 2004;175:494–502.Google ScholarPubMed
51.Dinerman, JL, Dawson, TM, Schell, MJ, Snowman, A, Snyder, SH.Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. Proc Natl Acad Sci U S A 1994;91:4214–4218.CrossRefGoogle ScholarPubMed
52.Knowles, RG, Moncada, S.Nitric oxide synthases in mammals. Biochem J 1994;298:249–258.CrossRefGoogle ScholarPubMed
53.Venturini, G, Colasanti, M, Fioravanti, E, Bianchini, A, Ascenzi, P.Direct effect of temperature on the catalytic activity of nitric oxide synthases types I, II, and III. Nitric Oxide 1999;3:375–382.CrossRefGoogle ScholarPubMed
54.Harvey, BH, Nel, A.Role of aging and striatal nitric oxide synthase activity in an animal model of tardive dyskinesia. Brain Res Bull 2003;61:407–416.CrossRefGoogle Scholar
55.Southam, E, Garthwaite, J.Comparitive effects of some nitric oxide donors on cyclic GMP levels in rat cerebellar slices. Neurosci Lett 1991;130:107–111.CrossRefGoogle Scholar
56.De Vente, J, Hopkins, DA, Markerink-Van Ittersum, M et al. Distribution of nitric oxide synthase and nitric oxide-receptive, cyclic GMP-producing structures in the rat brain. Neuroscience 1998;8:207–241.CrossRefGoogle Scholar
57.Uzbay, IT, Elik, T, Aydin, A, Kayir, H, Tokokgoz, S, Bilgi, C.Effects of chronic ethanol administration and ethanol withdrawal on cyclic guanosine 3,5- monophosphate (cGMP) levels in the rat brain. Drug Alcohol Depend 2004;74:55–59.CrossRefGoogle ScholarPubMed
58.Hows, MEP, Organ, AJ, Murray, S et al. High-performance liquid chromatography/tandem mass spectrometry assay for the rapid high sensitivity measurement of basal acetylcholine from microdialysates. Proceedings 50th ASMS Conference on Mass Spectrometry and Allied Topics. 2002;593–594.Google Scholar
59.Atri, A, Sherman, SJ, Norman, KA et al. Blockade of central cholinergic receptors impairs new learning and increases proactive interference in a word paired-associate memory task. Behav Neurosci 2004;118:223–236.CrossRefGoogle Scholar
60.Rada, P, Colasante, C, Skirzewski, M, Hernandez, L, Hoebel, B.Behavioral depression in the swim test causes a biphasic, long-lasting change in accumbens acetylcholine release, with partial compensation by acetylcholinesterase and muscarinic-1 receptors. Neuroscience 2006;141:67–76.CrossRefGoogle ScholarPubMed
61.Russell, RW, Overstreet, DH.Mechanisms underlying sensitivity to organophosphorus anticholinesterase compounds. Prog Neurobiol 1987;28:97–129.CrossRefGoogle ScholarPubMed
62.Overstreet, DH.Behavioral characteristics of rat lines selected for differential hypothermic responses to cholinergic or serotonergic agonists. Behav Genet 2002;32: 335–348.CrossRefGoogle ScholarPubMed
63.Overstreet, DH, Russell, RW, Crocker, AD, Gillin, C, Janowsky, DS.Genetic and pharmacological models of cholinergic supersensitivity and affective disorders. Experientia 1988;44:465–472.CrossRefGoogle ScholarPubMed
64.Diorio, D, Viau, V, Meaney, MJ.The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress. J Neurosci 1993;13:3839–3847.CrossRefGoogle ScholarPubMed
65.Herman, JP, Cullinan, WE.Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis. Trends Neurosci 1997;20:78–84.CrossRefGoogle ScholarPubMed
66.Miller, GE, Cohen, S.Psychological interventions and the immune system: a meta-analytic review and critique. Health Psychol 2001;20:47–63.CrossRefGoogle ScholarPubMed
67.Mayberg, HS.Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 1997;9:471–481.Google ScholarPubMed
68.Newport, DJ, Nemeroff, CB.Stress and depression: from vulnerability to treatment. Eur Neuropsychopharmacol 2000;10:164–165.CrossRefGoogle Scholar
69.Anand, A, Li, Y, Wang, Y et al. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry 2005;57:1079–1088.CrossRefGoogle ScholarPubMed
70.Adem, A, Jolkkonen, M, Bogdanovic, N, Islam, A, Karlsson, E.Localization of M1 muscarinic receptors in rat brain using selective muscarinic toxin-1. Brain Res Bull 1997;44: 597–601.CrossRefGoogle ScholarPubMed
71.Lamprea, MR, Cardenas, FP, Silveira, R, Morato, S, Walsh, TJ.Dissociation of memory and anxiety in a repeated elevated plus maze paradigm: forebrain cholinergic mechanisms. Behav Brain Res 2000;117:97–105.CrossRefGoogle Scholar
72.Zaborszky, L, Duque, A.Local synaptic connections of basal forebrain neurons. Behav Brain Res 2000;115: 143–158.CrossRefGoogle ScholarPubMed
73.Sarter, M, Bruno, JP.Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience 2000;95:933–952.CrossRefGoogle ScholarPubMed
74.Mark, GP, Rada, PV, Shors, TJ.Inescapable stress enhances extracellular acetylcholine in the rat hippocampus and prefrontal cortex but not the nucleus accumbens or amygdala. Neuroscience 1996;74:767–774.CrossRefGoogle ScholarPubMed
75.Pepeu, G, Giovannini, MG.Changes in acetylcholine extracellular levels during cognitive processes. Learn Mem 2004; 11:21–27.CrossRefGoogle ScholarPubMed
76.Harvey, BH, Naciti, C, Brand, L, Stein, DJ.Endocrine, cognitive and hippocampal/cortical 5HT1A/2A receptor changes evoked by a time dependent sensitisation (TDS) stress model in rats. Brain Res 2003;983:97–107.CrossRefGoogle ScholarPubMed
77.Harvey, BH, Brand, L, Jeeva, Z, Stein, DJ.Cortical/ hippocampal monoamines, HPA-axis changes and aversive behavior following stress and re-stress in an animal model of post traumatic stress disorder. Physiol Behav 2006;87: 881–890.CrossRefGoogle Scholar
78.Kulkarni, SK, Dhir, A.Current investigational drugs for major depression. Expert Opin Investig Drugs 2009;18: 767–788.CrossRefGoogle ScholarPubMed
79.Joca, SR, Ferreira, FR, Guimarães, FS.Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems. Stress 2007;10:227–249.CrossRefGoogle ScholarPubMed
80.Domek-Lopacinska, K, Strosznajder, JB.Cyclic GMP metabolism and its role in brain physiology. J Physiol Pharmacol 2005;56:5–34.Google ScholarPubMed
81.Harvey, BH, Carstens, ME, Taljaard, JJF.Antagonism of a novel cholinotropic property of lithium by scopolamine. S Afr J Sci 1990;86:265–269.Google Scholar
82.Harvey, BH, Carstens, ME, Taljaard, JJF.Lithium modulation of cortical cyclic nucleotides: evidence of the Yin-Yang hypothesis. Eur J Pharmacol 1990;175:128–136.CrossRefGoogle ScholarPubMed
83.Kendler, KS, Thornton, LM, Gardner, CO.Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry 2001;158:582–586.CrossRefGoogle ScholarPubMed
84.Montoliu, C, Rodrigo, R, Monfort, P et al. Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications. Metab Brain Dis 2010;25:39–48.CrossRefGoogle ScholarPubMed
85.Harvey, BH, Carstens, ME, Taljaard, JJ.Evidence that lithium induces a glutamatergic: nitric oxide-mediated response in rat brain. Neurochem Res 1994;19:469–474.CrossRefGoogle ScholarPubMed
86.Duman, RS, Malberg, J, Thome, J.Neuronal plasticity to stress andantidepressant treatment. Biol Psychol 1999;46: 1181–1191.CrossRefGoogle ScholarPubMed
87.Palmer, GC, Duszynski, CR.Regional cyclic GMP content in incubated tissue slices of rat brain. Eur J Pharmacol 1975;32:375–379.CrossRefGoogle ScholarPubMed
88.Palmer, GC, Chronister, RB, Palmer, SJ.Cholinergic agonists and dibutyryr cyclic guanosine monophosphate inhibit the norepinephrine-induced accumulation of cyclic adenosine monophosphate in the rat cerebral cortex. Neuroscience 1980;5:319–322.CrossRefGoogle ScholarPubMed
89.Liebenberg, N, Wegener, G, Harvey, BH, Brink, CB.Investigating the role of protein kinase-G in the antidepressant-like response of sildenafil in combination with muscarinic acetylcholine receptor antagonism. Behav Brain Res 2010;209:137–141.CrossRefGoogle ScholarPubMed
90.Wegener, G, Volke, V, Harvey, BH, Rosenberg, R.Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 2003;959:128–134.CrossRefGoogle Scholar
91.Reierson, GW, Mastronardi, CA, Licinio, J, Wong, M-L.Repeated antidepressant therapy increases cyclic GMP signaling in rat hippocampus. Neurosci Lett 2009;466: 149–153.CrossRefGoogle ScholarPubMed
92.Prast, H, Fischer, H, Werner, E, Werner-Felmayer, G, Philippu, A.Nitric oxide modulates the release of acetylcholine in the ventral striatum of the freely moving rat. Naunyn Schmiedebergs Arch Pharmacol 1995;352:67–73.CrossRefGoogle ScholarPubMed
93.Kopf, SR, Benton, RS, Kalfin, R, Giovannine, MG, Pepeu, G.NO synthesis inhibition decreases cortical acetylcholine release and impairs retention of a conditioned response. Brain Res 2001;894:141–144.CrossRefGoogle ScholarPubMed
94.Buchholzer, ML, Klein, J.NMDA-induced acetylcholine release in mouse striatum: role of NO synthase isoforms. J Neurochem 2002;82:1558–1560.CrossRefGoogle ScholarPubMed
95.Devan, BD, Sierra-Mercado, D Jr, Jimenez, M et al. Phosphodiesterase inhibition by sildenafilcitrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol Biochem Behav 2004;9:691–699.CrossRefGoogle Scholar
96.Patil, CS, Jain, NK, Singh, VP, Kulkarni, SK.Cholinergic-NO-cGMP mediation of sildenafil-induced antinociception. Indian J Exp Biol 2004;42:361–367.Google ScholarPubMed
97.Beavo, JA.Cylic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725–748.CrossRefGoogle Scholar
98.Soderling, SH, Beavo, JA.Regulation of cAMP and cGMP signaling. New phosphodiesterases and new functions. Curr Opin Cell Biol 2000;12:174–179.CrossRefGoogle ScholarPubMed